With the advent of immunotherapy, the action of checkpoint inhibitors such as anti-PD-1 (anti-programmed death-1) and anti-PD-L1 (anti-programmed death-ligand 1) has been increasingly studied in NPC [12]. Here, CD274 is linked to nasopharyngeal carcinoma.